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Background: The pimprinine family of compounds represent very important and promising microbial metabolites
for drug discovery. However, their ability in inhibiting viral infections has not yet been tested.
Methods: The antiviral activity of the pimprinine family of compounds was evaluated by determining the
cytopathic effect (CPE), cell viability or plaque-forming unit (PFU), and virus yield. The mechanism of action against
EV71 was determined from the virucidal activity, and effective stage and time-of-addition assays. The effects on
EV71 replication were evaluated further by determining viral RNA synthesis, protein expression and cells apoptosis
using the SYBR Green assays, immunofluorescence assays and flow cytometric assays, respectively.
Results: Pimprinethine, WS-30581 A and WS-30581 B inhibited EV71-induced CPE, reduced progeny EV71 yields, as
well as prevented EV71-induced apoptosis in human rhabdomyosarcoma (RD) cells. These compounds were found
to target the early stages of the EV71 replication in cells including viral RNA replication and protein synthesis. They
also showed antiviral activity against ADV-7, and were slightly active against CVB3, HSV-1 and H1N1 with a few
exceptions. Pimprinine was slightly active or inactive against all the viruses tested. The mechanisms by which these
compounds act against the viruses tested may be similar to that demonstrated for EV71.
Conclusion: The data described herein demonstrate that the pimprinine family of compounds are inhibitors
effective against the replication of EV71 and ADV-7, so they might be feasible therapeutic agents for the treatment
of viral infections.
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Enterovirus 71 (EV71) is a single positive-stranded
RNA virus that belongs to the Enterovirus genus of the
Picornaviridae family. It was first isolated and character-
ized from cases of neurological disease in the United
States in 1969 [1], subsequent outbreaks of EV71 infec-
tions have been reported around the world especially in
the Asia-Pacific region [2-7], which mainly affected young
children. Clinical manifestations have ranged from mild
hand-foot-mouse disease (HFMD) to severe encephalitis
and pulmonary edema and even death [8,9]. According to
reports from the Chinese Center for Disease Control
and Prevention (CCDC), HFMD was listed as the most* Correspondence: shiliqiao_75@163.com; 18627186188@126.com
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unless otherwise stated.common category-C infectious disease from 2009 to 2011,
based on incidence and death rate, with more than 500
deaths in over 1,600,000 cases of EV71 infection reported
in China in 2011 alone [9]. There is currently no vaccine
or specific medication for EV71 infections [9], highlighting
the urgency and significance of developing suitable anti-
EV71 agents. Hence, greater effort needs to be put into
developing drugs to conquer the EV71 infections.
Coxsackievirus B3 (CVB3) [10], adenovirus 7 (ADV-7)
[11], herpes simplex virus 1 (HSV-1) [12] and influenza
virus (H1N1) [13] infections cause common diseases in
humans. However, there exists no specific drug that has
been approved for the treatment of CVB3 and ADV-7
infections [11]. Also, drug-resistant viral strains and several
side effects of drugs used to treat HSV-1 and H1N1, have
become more prevalent [14,15]. These emerging problems. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Chemical structures of pimprinine and its analogues.
Pimprinine: R1 = CH3; Pimprinethine: R1 = CH2CH3; WS-30581 A:
R1 = CH2CH2CH3; WS-30581 B: R1 = CH2CH2CH2CH3.
Table 1 Antiviral activity against EV71, cytotoxicity, and
selectivity index (SI) of pimprinine, pimprinethine,
WS-30581 A and WS-30581 B in RD cells
Tested compound CC50a (μM) EC50b (μM) EC90c (μM) SId
Pimprinine 1455 ± 27e 89 ± 18 149 ± 12 16
Pimprinethine 835 ± 20 35 ± 4 42 ± 3 24
WS-30581 A 363 ± 13 16 ± 1 26 ± 6 23
WS-30581 B 229 ± 10 11 ± 3 18 ± 2 21
Ribavirinef 1230 ± 355 102 ± 68 136 ± 49 12
aCC50, compound concentration required to reduce cell viability by 50%.
bEC50, compound concentration required to achieve 50% protection from
virus-induced cytopathogenicity.
cEC90, compound concentration required to achieve 90% virus yield reduction.
dSI (selectivity index), ratio CC50/EC50.
eValues represent the mean ± SD of three independent experiments.
fRibavirin, used as a positive control.
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antiviral drugs.
Indole alkaloids have received significant attention
during the past decade due to their diverse biological
activities. Members of the pimprinine (5, 30-indolyl-2-
methyloxazole) family, pimprinethine (pimprinine (n-ethyl)
homologue), WS-30581 A and WS-30581 B (pimprinine
(n-propyl and n-butyl) derivatives), as natural indole alka-
loids, have been isolated from various microbial fermenta-
tion broths and have been demonstrated to exhibit broad
pharmaceutical activities [16-18]. Pimprinine is an effective
inhibitor of monoamine oxidase (MAO) and has been
reported to have promising anticonvulsant and anti-
tremorine activity [19]; WS-30581 A and WS-30581 B
exhibit significant inhibitory effects on platelet aggre-
gation and have anti-thrombolytic activity in vitro [18].
Nitrogen- and oxygen- containing five-membered hetero-
cyclic compounds have been reported to be structures that
play key roles in the activities of many biologically inter-
esting natural products and useful therapeutic agents [20].
Therefore, the pimprinine family of compounds may rep-
resent a group of very important and promising microbial
metabolites in the search for novel drugs. However, the
ability of these compounds to inhibit viral infections has
not yet been tested. Herein, we report that pimprinine,
pimprinethine, WS-30581 A and WS-30581 B are inhibi-
tors of EV71 infection in vitro, and we have identified
their preliminary modes of action. Moreover, the antiviral
activities of the pimprinine family of compounds against
CVB3, ADV-7, HSV-1 and H1N1 infections were also
described for the first time.
Results
The antiviral activity of pimprinine, pimprinethine,
WS-30581 A and WS-30581 B against EV71
The antiviral activity of pimprinine and its analogues
pimprinethine, WS-30581 A and WS-30581 B (Figure 1),
against EV71 based on inhibition of virus-induced cyto-
pathic effects (CPE) in human rhabdomyosarcoma (RD)
cells was examined. The cytotoxic effects were also eval-
uated. Table 1 shows that the effective concentrations
50% (EC50s) of pimprinine, pimprinethine, WS-30581 A
and WS-30581 B were 89 μM, 35 μM, 16 μM and 11 μM
against EV71, respectively and the selectivity indexes (SI)
were 16, 24, 23 and 21, respectively. These compounds
showed more potent inhibitory activity against EV71 than
ribavirin (EC50 = 102 μM, SI = 12). As shown in Figure 2A,
the EV71-infected cells showed a rounded-up appearance
and detached from the dish in the absence of tested
compounds. Treatments of RD cells with pimprinine,
pimprinethine, WS-30581 A and WS-30581 B produced a
slight protection against EV71-induced CPE at the
lower concentrations, while a nearly complete inhib-
ition of EV71-induced CPE was observed at the higherconcentrations, which was used for the subsequent experi-
ments in this study.
The protective effects of pimprinine, pimprinethine,
WS-30581 A and WS-30581 B on EV71-induced CPE
formation were confirmed by quantifying the effects on
progeny viral yield. To this end, the confluent monolayers
of RD cells in a 96-well plate were infected with 100
TCID50 of EV71 mixed with or without the tested com-
pounds at various concentrations. After 10 h, the culture
media and cell lysates were collected following freeze-
thaw cycles and then subjected to virus titration. Treat-
ments with tested compounds resulted in efficient and
concentration-dependent reductions in progeny virus ti-
ters (Figure 2B), with a reduction of approximately 0.5 log
for pimprinine and a 3.0 log reduction for pimprinethine,
A(a) Control   (b) Pimprinine  (c)Pimprinethine  (d) WS-30581 A   (e) WS-30581B
B 
C
Cell 160 µM              80 µM                40 µM 40 µM
Virus 80 µM 40 µM                10 µM 10 µM
Pimprinine (104 TCID50)






Figure 2 Antiviral activities of pimprinine, pimprinethine, WS-30581 A and WS-30581 B against EV71 in a dose-dependent manner in
RD cells. (A) The inhibition of virus-induced CPE. RD cells were infected with 100 TCID50 of EV71 mixed with serial dilutions of tested compounds
for 1 h at 37°C, the inocula were aspirated and the cells were incubated with DMEM/tested compounds at 37°C, 5% CO2 for 48 h, the antiviral
effects were observed in terms of cellular morphology. (B) The inhibition of progeny virus yield. RD cells were infected with 100 TCID50 of EV71 in
the absence or presence of tested compounds, the culture media and cell lysates were collected for virus titration at 10 h pi. The viral titers were
presented as Log10 TCID50/mL. (C) Analysis of the dependence of the EC50s on virus titers. RD cells were infected with various TCID50 of EV71,
the tested compounds were added as described in (A), cell viability was determined at 48 h pi and the EC50 were calculated. The x-axis is in a
base 10 logarithmic scale. Each value is the mean of triplicate assays ± standard deviation (SD).
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group at a concentration of 80 μM. As a positive control,
there was an approximate 2.0 log reduction in progeny
virus titers with ribavirin at a concentration of 160 μM.
The EC90 values derived from progeny viral yield assays
are presented in Table 1.
To test the dependence of the EC50 values on virus
concentrations, the RD cells were infected with various
TCID50 of EV71 in the presence of a series dilutions of
tested compounds for 1 h at 37°C. Inocula were removed
and the cells were incubated further with various concen-
trations of the tested compounds in Dulbecco’s modified
Eagle’s medium (DMEM) for 48 h. Antiviral activities were
evaluated by determining cell viability with an 3-(4, 5-
dimethylthiazol-2-yl)-2, 5- diphenyltetrazo-liumbromide
(MTT)-method and the EC50s were calculated. As seen in
Figure 2C, the EC50 values for pimprinethine, WS-30581
A and WS-30581 B were similar, with slight variations
independently of the virus inoculum. Inhibition was elimi-
nated when the virus concentration increased to above
104 TCID50. For pimprinine, the anti-EV71 activity ap-
peared to be largely dependent of the virus inoculum, and
there was no inhibition observed when the concentration
of virus increased to over 104 TCID50. These results sug-
gest that these compounds can be overwhelmed by exces-
sive amounts of virus.
Preliminary studies on the mechanisms of action of
pimprinethine, WS-30581 A and WS-30581 B
Due to the lesser antiviral efficacy of pimprinine compared
with the other compounds tested in our assay, pimpri-
nethine, WS-30581 A and WS-3058 B were selected to
further investigate the mechanisms of the antiviral action.
To determine if the pimprinine family of compounds
inactivated virions directly, 103 TCID50 of EV71 suspen-
sion was incubated in the presence of 80 μM pimpri-
nethine, 40 μM WS-30581 A or 40 μM WS-30581 B for
24 h at 4°C. Subsequently, the viral titers in the mixture
were measured by inoculating 10-fold dilutions of the
mixtures beyond the effective concentrations of the com-
pounds into the host cells. The TCID50 were calculated by
the Reed and Muench method [21] on day 2 post inocu-
lation; 160 μM ribavirin was used as a positive control. No
significant difference was found between virus titers of the
mixture for EV71 with and without the tested compounds
present (data not shown). This evidence suggests that
all compounds are not virucidal with respect to the viruses
tested.
To identify the stage in the viral life cycle that is
affected by the pimprinethine, WS-30581 A and WS-
30581 B, the assays were performed using three different
treatment protocols. As shown in Figure 3A and B, all of
the tested compounds exhibited the most powerful thera-
peutic effects that the viability rates of the infected cellstreated with pimprinethine, WS-30581 A and WS-30581
B at concentrations of 80 μM were almost 100%. The virus
titers of compounds-treated cells were much lower (ap-
proximately 5.0 log reduction for the three compounds)
than those from untreated cells. On the contrary, a grad-
ual loss in the antiviral effects was observed when the
drugs were added just before or during infection. Ribavirin
showed the same results as the tested compounds. These
results suggest that pimprinethine, WS-30581 A and WS-
30581 B are not preventive against EV71, neither do they
inhibit adsorption of EV71, they mainly block the post-
attachment stage of a viral infection.
This conclusion on adsorption inhibition was confir-
med by intracellular virus titrations using the TCID50
method. As can be seen in Figure 3C, no significant
decrease in the virus titer during virus attachment in the
presence of either pimprinethine, WS-30581 A, WS-30581
B or ribavirin was detected, confirming that virus ad-
sorption is not quantitatively affected by any of these
compounds.
The possibility was tested that viral release from cells is
affected by pimprinethine, WS-30581 A and WS-30581 B.
Ribavirin was, once again, used as a positive control.
Figure 3D shows that the virus titers from infected RD
cells, the supernatants or total solutions (cell lysis solutions
and the supernatants) treated with tested compounds have
been significantly reduced, and a stronger inhibition of
virus titers from the infected RD cells than those from the
supernatants was observed, implying that the release of
EV71 had been unaffected.
Pimprinethine, WS-30581 A and WS-30581 B affect viral
early steps of replication in cells
In order to further understand the mechanisms of pim-
prinethine, WS-30581 A and WS-30581 B action against
EV71 propagation in cells, a time-of-addition experiment
was performed. As shown in Figure 4, when the tested
compounds were present for the whole course of the
replication cycle (-1–10), the titers of the progeny virus
were reduced, which was similar to that for the addition
of drugs during the 0–10 h and 2–10 h stage after viral
infection (pi). For drugs treatments during other periods
following EV71 infection, a gradual increase in viral
yields was observed, reflecting a loss of the antiviral effects
of the compounds. The control compound, ribavirin, ex-
hibited a very similar trend. Results from this experiment
indicate that these compounds act mainly at the early
stage of the viral replication post infection.
Pimprinethine, WS-30581 A and WS-30581 B inhibit
strongly viral replication in RD cells
To investigate the effects of pimprinethine, WS-30581 A
and WS-30581 B on EV71 replication further, the effi-
cacy of the compounds in inhibiting progeny viral yields,
Figure 3 Analysis of the modes of action of pimprinethine, WS-30581 A and WS-30581 against EV71. (A-B) Analysis of the effective stage.
The RD cells were incubated under serial 2-fold dilutions of tested compounds before, simultaneously or after EV71 (100 TCID50) inoculation.
Antiviral effects were detected by measuring cell viability (A) and the progeny virus yields (80 μM) (B) after 48 h of infection. (C) Analysis of the
effects on EV71 adsorption. Mock- or 160 μM pimprinethine, 80 μM WS-30581A and 80 μM WS-30581 B-treated EV71 (104TCID50) was inoculated
onto RD cells and adsorbed for 2 h, the infected cells were harvested and then subjected to virus titrations using the TCID50 method. (D) The
effects on EV71 release from RD cells. RD cells infected with 100 TCID50 of EV71 were incubated with tested compounds for 12 h, both of cells
and supernatants (intra- and extracellular), or one of which was harvested separately for determination of virus yield. Mock: no infection; VC, virus
control. Values represent the means ± SDs of three independent experiments. *P <0.05, compared with virus control group.
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were analyzed. Infected cells treated with or without
80 μM pimprinethine, 40 μM WS-30581 A or 40 μMWS-30581 B were harvested after 4, 8, 24 and 36 h p.i. in
order to determine the progeny viral yields using the Reed
and Muench method. Quantitative reverse transcription
Figure 4 Time-of-addition assay. 80 μM pimprinethine, 40 μM
WS-30581 A or 40 μM WS-30581 B were added to RD cells at
different time periods after EV71 infection. At 12 h pi, the progeny
virus yield was determined (-1–0 h: viral infection period; 0–10 h: the
period for virus proliferation in the cells). Values are represented as
the means ± SDs. *P <0.05, compared with virus control group.
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munofluorescence analysis of harvested cells were also
carried out to determine the relative amounts of viral
RNA and viral protein, respectively.
As shown in Figure 5A and B, the virus titer and the
level of viral RNA continued to increase from 4 to 36 h
in the virus control cells, which indicated the virus was
actively replicating in the cells following the viral inocula-
tion. Notably, no obvious change obviously was observed
in the cells treated with compounds, and inhibitory effects
were the most prominent at 36 h p.i. This result implies
that pimprinethine, WS-30581 A and WS-30581 B target
viral replication in RD cells.
The influence of the tested compounds on EV71 repli-
cation at the level of translation was also determined.
Immunofluorescence foci of viral protein were not ob-
served in the mock-infected control (Figure 5C-a), which
suggested that the antibody was specific for EV71. The
green immunofluorescence foci in the virus control group
(Figure 5C-b) were significantly more abundant than that
in the compounds-treated cells (Figure 5C-c, d, e), indicat-
ing that the viral protein synthesis was suppressed by the
compounds as a result of their cumulative inhibitory
action on viral RNA synthesis. These results lead us to
propose that pimprinethine, WS-30581 A and WS-30581
B suppress EV71 replication by inhibiting viral RNA and
protein synthesis.
Pimprinethine, WS-30581 A and WS-30581 B inhibit
EV71-induced apoptosis
Previous studies have shown that EV71 induces apoptosis
in infected cells when viral protein synthesis occurs,
whereas neither viral adsorption, internalization, entry,
uncoating, nor viral RNA replication are required to trig-
ger this apoptosis [22]. Flow cytometry was performed
to investigate the effects of pimprinethine, WS-30581 Aand WS-30581 B on virus-induced cell apoptosis. As il-
lustrated in Figure 6, RD cells infected with EV71 (virus
control) showed a significant fluorescence drift to the
right (representative of early apoptosis) and to the
upper-right quadrant (representative of late apoptosis or
death) in comparison to the mock-infected cells. While
fluorescence drifting could be hardly observed with ad-
dition of pimprinethine, WS-30581 A and WS-30581 B.
These data demonstrate that these compounds can ef-
fectively inhibit the EV71-induced apoptosis in RD cells,
which indirectly reflects their inhibition of viral protein
synthesis.
Antiviral activities of pimprinine family compounds
towards other human viruses
The antiviral efficacies of pimprinine, pimprinethine, WS-
30581 A and WS-30581 B against representatives of several
classes of virus were also evaluated in cell-based assays.
The viruses used for testing included: non-enveloped
RNA virus, CVB3; enveloped RNA virus, influenza virus
A/human/Hubei/86/2009 (H1N1); enveloped DNA virus,
HSV-1 and non-enveloped DNA virus, ADV-7. Ribavirin,
amantadine and acyclovir were used as reference in-
hibitors. Cytotoxicity on Hep-2, HeLa and MDCK,
human cell lines suitable for the replication of these
viruses respectively, were also evaluated using an MTT
method.
Since CVB3, ADV-7 and HSV-1 infections caused
marked CPE, we started by evaluating the antiviral proper-
ties of these compounds through the analysis of CPE
formation in CVB3-infected Hep-2 cells, ADV-7-infected
HeLa cells and HSV-1-infected Hep-2 cells. Figure 7
shows that these compounds could protect cells from
virus-induced CPE. Morphologically, the cells infected
with viruses, in the absence of tested compounds, showed
typical CPE such as the rounding and formation of giant
multinucleated syncytia (Figure 7-B) compared with mock
infection (Figure 7-A). CPEs of infected cells were inhibited
by treating them with 160 μM pimprinine (Figure 7-C),
80 μM pimprinethine (Figure 7-D), 40 μM WS-30581 A
(Figure 7-E) or 40 μM WS-30581 B (Figure 7-F).
These compounds exhibited high to moderate activity
against the different viruses, the rank order of virus
sensitivity was ADV-7 > CVB3 > HSV-1 > H1N1 (Table 2).
All compounds were inhibitory against ADV-7 and CVB3,
and WS-30581 A and WS-30581 B were approximately
7-fold more active than ribavirin (Table 2). Pimpri-
nethine, WS-30581 A and WS-30581 B also exhibited
significant antiviral activity against HSV-1, and were
capable of achieving approximately 80% inhibition of
HSV-1-induced plaque formation. Acyclovir exhibited
strong inhibition of HSV-1 (Table 2). However, WS-30581
A and WS-30581 B produced less than 70% inhibition
of H1N1 infection and pimprinine and pimprinethine
A B
C













Figure 5 (See legend on next page.)
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Figure 5 Effects of pimprinethine, WS-30581 A and WS-30581 B on EV71 replication in RD cells. RD cells infected with 100 TCID50 of
EV71 were incubated in the absence (VC) or presence of 80 μM pimprinethine, 40 μM WS-30581 A or 40 μM WS-30581 B and harvested at the
indicated times pi. (A) The progeny viral yields were determined. Dashed lines indicate virus titer less than the detectable dose. (B) The total RNA
was extracted from cells and culture supernatants and EV71 RNA levels were measured. Cellular actin amplification was used for normalization.
The △△CT data were calculated from three independent experiments. *P <0.05, compared with the virus control group. (C) EV71-protein was
determined by indirect immunofluorescence using a mouse anti-enterovirus 71 monoclonal antibody and an Alexa Fluor 488-Conjugated
Affinipure Goat Anti-Mouse IgG (H + L). The nucleus was stained with DAPI and the green foci indicate the presence of EV71 protein.
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tadine produced a good anti-H1N1 effect in this assay
(Table 2).
Virus yield reduction assays were also carried out to
evaluate further the protective effects of the tested com-
pounds. Pimprinine, pimprinethine, WS-30581 A and
WS-30581 B showed activities that were similar to the
CPE inhibition results. The dose-dependent effectiveness
for antiviral activity, expressed as EC90s, is shown in
Table 2.
Pimprinethine, WS-30581 A and WS-30581 B also inhibit
CVB3, ADV-7, HSV-1 and H1N1 replication in cells
To investigate which stage pimprinethine, WS-30581 A
and WS-30581 B inhibit viruses infection at, various





Figure 6 The inhibitory effects of pimprinethine, WS-30581 A and WS
(A) or were infected with 100 TCID50 of EV71, after viral adsorption, RD cel
pimprinethine (C), 40 μM WS-30581 A (D) and 40 μM WS-30581 B (E) for 3
propidium iodide and measured using flow cytometry. Values are represenHep-2 cells, HeLa cells and MDCK cells before (before
infection), simultaneously (during infection) or after (post
infection) CVB3, ADV-7 and H1N1 inoculation. CPEs
were observed and the viability of the cells was deter-
mined with MTT assays after incubation at 37°C for 48 h.
For HSV-1, the inhibitory effects were measured using
plaque reduction assays on inoculated Hep-2 cells.
As shown in Figure 8, all compounds analyzed showed
dose-dependent inhibitory effects on viral replication
under the conditions of post-infection. Treatment with
the compounds before infection or during virus infection
produced little or no antiviral effect on any of the vi-
ruses, indicating that the antiviral target is the replica-
tion stage of the virus. This finding suggests that similar
modes of inhibition operate in all of the viruses tested.
These results are compatible with the conclusion drawn Pimprinethine       WS-30581 A   C D
-30581 B on EV71-induced apoptosis. RD cells were left untreated
ls were incubated in the absence (B) or presence of 80 μM
6–48 h, the cells were stained with Annexin-V- fluorescein and
ted as means ± SDs. *P <0.05, compared with virus control group.
A B C D E F
Figure 7 Antiviral activity of pimprinine, pimprinethine, WS-30581 A and WS-30581 B against CVB3, ADV-7 and HSV-1. The Hep-2 and
HeLa cells were left untreated (A) or infected with 100 TCID50 of CVB3, ADV-7 and HSV-1, after virus inoculation, the infected cells were mixed
without (B) or with 160 μM pimprinine (C), 80 μM pimprinethine (D), 40 μM WS-30581 A (E) or 40 μM WS-30581 B (F) for 1 h at 37°C respectively,
the inocula were aspirated and the cells were further incubated with DMEM/tested compounds at 37°C, 5% CO2 for 48 h, the antiviral effects
were observed with respect to cellular morphology.
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and WS-30581 B target the viral replication stage.
Discussion
EV71 infections have received much attention because
of the increased incidences and lack of vaccines and
effective therapies. Natural substances offer an interest-
ing pharmacological perspective for the development of
novel antiviral drugs with broad-spectrum antiviral prop-
erties and novel modes of action. Some natural indole
alkaloid compounds have been proven to have antiviral
potential against dengue virus and HSV-2 [23,24]. In this
study, we report novel findings that pimprinethine, WS-
30581 A and WS-30581B, as natural indole alkaloids, were
effective inhibitors of the replication of EV71 and ADV-7,
with slight inhibitory activity against CVB3, HSV-1 and
H1N1 (with a few exceptions). Pimprinine, however was
only slightly inhibitory or inactive against all of these
viruses.
The chemical structures of pimprinine, pimprinethine,
WS-30581 A and WS-30581 B differ by a methyl group
(Figure 1A), which must ultimately lead to the variations
in antiviral activity and cytotoxicity. Thus, compounds
with better antiviral efficacies could possibly be produced
by modifying these structures, which could also be con-
firmed further by some of the synthetic pimprinethine
analogues with various more excellent biological activ-
ities [25,26].
EC50 values derived from three-day assays are usually
more predictive of in vivo efficacy than 48-hr assays. We
also measured the CPEs of the cells infected with the
five viruses after three days of incubation with tested
compounds in 96-well plates, where the virus inoculum
reached >90% CPE. The results were similar to thoseobtained from treatments with tested compounds for
two days (data not shown). This also showed the effect-
iveness and stability of these compounds against viral
infections, especially of EV71.
The SI of pimprinethine, WS-30581 A and WS-30581
B against EV71 were better than that of the control
compound, ribavirin, in RD cells (Table 1). Although all
tested compounds were more toxic than ribavirin, how-
ever they could inhibit the replication of EV71 at lower
concentrations. This provides evidence that the com-
pounds exhibit cytotoxic effects on the host cells after
an antiviral role, rather than destroying cells directly and
hence inhibiting viral proliferation within them. For
compounds with lower SI values, it is difficult to refute
the possibility that they may damage cells or slow down
cell metabolism enough to inhibit virus production at or
near their EC50. In our assays the EC50s of all com-
pounds tested, against five human viruses, were mea-
sured by the observation of CPE microscopically and
from the determination of cell viability with MTT assays
and virus yield reduction assays. CPE can reflect the sur-
face morphology of infected cells, while the MTT assay
measures the level of cellular metabolism, and virus yield
assays tests viral multiplication directly in infected cells.
The similarity of the EC50s obtained for all compounds
using the three different approaches suggests that the
compounds alone do not inhibit cell growth. Further-
more, the successful use of pimprinine as a significant
protection against electrically induced convulsions in vivo
(80 mg/kg) [19] suggests that the toxicity observed in cell
culture may not be equivalent to that in vivo. Previous
research has demonstrated that the acute toxicity of
WS-30581 A in ddY mice by intraperitoneal injection
was above 250 mg/kg [18]. These findings suggest that the
Table 2 Inhibitory effects of pimprinine, pimprinethine,




CVB3 HSV-1 ADV-7 H1N1
CC50a 443 ± 35e 443 ± 35 1140 ± 181 899 ± 56
Pimprinine EC50b 95 ± 16 160 ± 18 150 ± 10 —
EC90c —f — 266 ± 14 —
SId 5 3 8 —
CC50 256 ± 49 256 ± 49 750 ± 30 577 ± 73
Pimprinethine EC50 22 ± 4 45 ± 3 33 ± 6 —
EC90 58 ± 9 — 63 ± 5 —
SI 12 6 23 —
CC50 72 ± 8 72 ± 8 217 ± 4 212 ± 18
WS-30581 A EC50 14 ± 4 18 ± 2 17 ± 18 38 ± 7
EC90 39 ± 4 — 43 ± 3 —
SI 5 4 13 6
CC50 83 ± 6 83 ± 6 354 ± 14 215 ± 28
WS-30581 B EC50 12 ± 2 14 ± 4 15 ± 2 24 ± 5
EC90 42 ± 6 — 48 ± 6 —
SI 7 6 24 9
CC50 1311 ± 385 1516 ± 243
Ribaviring EC50 90 ± 10 116 ± 19
EC90 103 ± 17 132 ± 22
SI 15 13
CC50 >2000
Acyclovirh EC50 11 ± 1
EC90 24 ± 5
SI >181
CC50 >2000
Amantadinei EC50 73 ± 8
EC90 90 ± 12
SI >27
aCC50, compound concentration required to reduce cell viability by 50%.
bEC50, compound concentration required to achieve 50% protection from
virus-induced cytopathogenicity.
cEC90, compound concentration required to inhibit 90% virus yield.
dSI (selectivity index), ratio CC50/EC50.
eValues represent the mean ± SD of three independent experiments.
f—, less than 50% or 90% inhibition; g, h, iRibavirin, acyclovir and amantadine,
used as positive controls.
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peutic applications.
Since the CC50 values for pimprinine and pimpri-
nethine have been found to be extremely high, the cyto-
toxic effects of all the tested compounds against RD
cells, and pimprinine and pimprinethine against HeLa,
Hep-2 and MDCK cells, have also been confirmed using
an ATPLite luminescence-based assay (Perkin Elmer,
Waltham, MA). The results were shown in Table 3. The
ATPLite assay may be more sensitive to cytotoxicitythan the MTT method. For RD and Hep-2 cells, similar
results were obtained, and for HeLa and MDCK cells,
the values of CC50 from the ATPLite assay were smaller
than those from MTT assays (Tables 1, 2 and 3).
The EV71 replication cycle can be divided into the fol-
lowing steps: viral attachment, entry, polyprotein transla-
tion and cleavage, viral RNA replication, assembly and
release [27]. These critical steps are currently considered
to be the targets for the development of antiviral agents
[28]. Picornavirus could complete its life cycle in 5–10 h
(approximately 8 h). Upon virus attachment and entry
into the host cell, an uncapping event occurs to release
the RNA genome into the cell. Cap-independent transla-
tion of the viral RNA takes place through the recruit-
ment of host replication machinery. Negative RNA
intermediates of the viral genome are also generated to
serve as templates for the replication of positive-sense
RNA viral genomes. These events have been predicted
to reach high levels at 3–4 h post infection. Progeny
virions are then self-assembled from the synthesized
viral proteins and RNA genomes, which begins in the
cytoplasm during the 4–6 h, and the release of virus
particles is conducted during the 6–10 h period [29-31].
In our assays, time-addition assays with pimprinethine,
WS-30581 A and WS-30581 B demonstrated that inhib-
ition of virus yields declined when RD cells were treated
with these compounds at more than 4 h post infection,
which was consistent with EV71 genomes replication
and protein synthesis being at a high level during 3–4 h
post viral infection. These compounds showed strong
activity against viral RNA synthesis, but not completely
inhibited viral protein synthesis. These results allow us
to conclude that there is a direct effect of the com-
pounds on viral RNA synthesis, and the inhibition of
viral protein synthesis by the compounds is the result of
their cumulative inhibitory action on viral RNA synthe-
sis. More detailed analyses of the mechanisms of action
of these compounds are currently being conducted.
To date several mechanisms of ribavirin action have
been proposed. These include: (a) Inhibition of inosine
monophosphate dehydrogenase (IMPDH) [32]; (b) Inhib-
ition of proinflammatory mediators induced by viral infec-
tion [33] and (c) Inducement of lethal mutagenesis after
incorporation during viral RNA synthesis, which leads to
a loss of total viral genomic RNA [34]. Pimprinethine,
WS-30581 A and WS-30581 B had greater antiviral activ-
ity than ribavirin, but similar results were obtained for all
of these compounds to determine the mechanisms of anti-
viral action. Therefore, it is conceivable that these antiviral
agents act according to some, but not all, of the mecha-
nisms of action that have been proposed for ribavirin.
Pimprinine is an MAO inhibitor, so it could be interest-
ing to find out whether other MAO inhibitors (such as




 HSV-1                                       H1N1
Figure 8 Analysis of effective stages of pimprinethine, WS-30581 A and WS-30581 B against four viruses: CVB3, ADV-7, HSV-1 and
H1N1. The cells were infected with different viruses, and incubated under serial 2-fold dilutions of tested compounds at the indicated periods
(before, simultaneously or after virus inoculation) following different procedures, the antiviral effects were detected by measuring of cell viability
(A: CVB3, B: ADV-7 and D: H1N1) or plaque formation (C: HSV-1). Mock: no infection; VC, virus control. Values represent the means ± SDs of three
independent experiments.
Table 3 Cytotoxicity of pimprinine, pimprinethine,
WS-30581 A and WS-30581 B in RD, Hep-2, HeLa and
MDCK cells
CC50a (μM)
Tested compound RD Hep-2 HeLa MDCK
Pimprinine 1263 ± 247 403 ± 53 940 ± 219 649 ± 77
Pimprinethine 656 ± 82 233 ± 36 550 ± 103 406 ± 48
WS-30581 A 313 ± 49 —b — —
WS-30581 B 267 ± 31 — — —
aCC50, compound concentration required to reduce cell viability by 50%.
b—, not done.
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activity against EV71 and CVB3 and found them to be
inactive. This suggests that the mode of antiviral action of
these compounds is likely to differ to their mechanisms of
anti- MAO action.
EV71 induced apoptosis has been considered to be an
important mechanism in disease pathogenesis [35].
Apoptosis leads to the spread of viral progeny, which
may cause viremia and severe central nervous system
complications. In this study, pimprinethine, WS-30581
A and WS-30581 B were found to have an obvious
inhibitory effect on EV71-induced apoptosis, which may
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severe consequences of EV71 infection.
Pimprinethine, WS-30581 A and WS-30581 B have
shown post-exposure activity on EV71-infected cells. We
also demonstrated that these compounds target the post-
infection stages of CVB3, ADV-7, HSV-1 and H1N1 life
cycles. Thus, the pimprinine family of compounds may be
safe and effective agents for therapeutic use against EV71
infection, and therapeutic agents for the adjuvant treat-
ment of other viral infections.
Conclusions
Pimprinethine, WS-30581 A and WS-30581 B exhibited
inhibitory activity against EV71 and ADV-7, slightly
activity against CVB3, HSV-1 and H1N1, with a few ex-
ceptions, in vitro. These compounds mainly act at the
early stage of the EV71 replication period. The mechanism
by which these antiviral agents act against other viral
infections may be similar to that shown for EV71. The
data described herein demonstrate that the pimprinine
family of compounds are effective therapeutic agents for
the treatment of EV71 infection. Here we have uncovered
new information about the scope of the biological activity
of the pimprinine family of compounds.
Materials and methods
Cells, viruses and tested compounds
Human rhabdomyosarcoma cells (RD), Human laryngeal
carcinoma cells (Hep-2), Human cervical carcinoma cells
(HeLa) and Madin-Darby canine kidney cells(MDCK)
(purchased from China Center for type Culture Collec-
tion, CCTCC) were maintained in DMEM (Gibco) sup-
plemented with 10% fetal bovine serum (FBS; Gibco), 100
U/mL of penicillin and streptomycin, and 2 mM L-glutam-
ine. EV71 (XiangYang-Hubei-09), CVB3 (Nancy strain),
ADV-7, HSV-1 and H1N1 were kind gifts from Professor
Zhanqiu Yang (Institute of Medical Virology, School of
Medicine, Wuhan University, China) and were propagated
in RD, Hep-2, HeLa and MDCK cell lines. Viral titers were
determined using the standard method of median tissue
culture infective dose (TCID50) on corresponding host cells
[21]. Pimprinine, pimprinethine, WS-30581 A and WS-
30581 B (Figure 1A) were isolated from Streptomyces sp.
WS-13317 and identified by comparing spectra to those in
the literature [18,36]. Amantadine, ribavirin and acyclovir
used as positive controls, were purchased from Sigma
Chemical Co. Stock solutions of drugs were prepared in di-
methyl sulfoxide (DMSO) at a final concentration of 0.1%
and diluted with maintenance medium (MM) consisting of
DMEM with 2% fetal bovine serum.
Determination of cell viability
Cell viability was assessed by an MTT assay, which func-
tions based on the reduction of a MTT into formazandye by active mitochondria. The cells were treated with
100 μL of MTT (1 mg/mL, Sigma) and incubated at 37°C
for 4 h. The reaction was blocked by DMSO and measured
in a microplate reader (Bio-Tek Instruments) at 492 nm.
The untreated control was arbitrarily set as 100%.
Plaque reduction assay
Confluent monolayers of Hep-2 cells, seeded in a 24-well
plate, were infected with HSV-1 at a density of 60–80
plaque-forming units (PFU) per well and treated with
media (pre-warmed DMEM containing 2% FBS, 0.8% low-
melting agarose) mixed with or without the serially diluted
tested compounds for the periods indicated following dif-
ferent procedures. The cells were incubated at 37°C until
plaques appeared, followed by fixing with 10% formalde-
hyde and staining with 0.5% crystal violet. The plaques
were counted by visual examination. The ratio of the
number of plaques in the treated group to that in the un-
treated control was calculated.
Antiviral activity and cytotoxicity
The antiviral activities of pimprinine, pimprinethine, WS-
30581 A and WS-30581 B against EV71, ADV-7, CVB3,
HSV-1 and H1N1 were determined according to inhib-
ition of virus-induced cytopathogenicity effects (CPE) in
acutely infected RD, HeLa, Hep-2 and MDCK cells. Con-
fluent cell monolayers in 96-well dishes were infected with
100 TCID50 of corresponding virus dilution mixed with
serial dilutions of tested compounds for 1 h at 37°C.
Inocula were aspirated and the cells were then incubated
with various concentrations of DMEM/tested compounds
at 37°C, 5% CO2 for 48 h. CPE were observed microscop-
ically and the viability of the cells was determined using
MTT assays. A plaque reduction assay was performed to
measure the inhibitory effects of the test compounds
against HSV-1 infection. The concentrations required for
the tested compounds to achieve 50% protection of cells
from virus-induced CPE were determined.
Adverse effects of pimprinine, pimprinethine, WS-30581
A and WS-30581 B on the host cells (RD, HeLa, Hep-2
and MDCK) were also assessed by means of the MTT-
method, by exposing uninfected cells to various concen-
trations of tested compounds for 48 h at 37°C, the viability
of the cells was subsequently determined. The 50% cell
cytotoxic concentrations (CC50s) of compounds were cal-
culated using SPSS software. SI were calculated from the
ratio of CC50: EC50.
Virus yield reduction assay
The virus suspension, serially diluted 10-fold with DMEM
containing 2% FBS, was inoculated to cells in a 96-well
plate. After 1 h incubation at 37°C in 5% CO2, unbinding
virus was washed out and DMEM maintenance medium
supplemented with 2% FBS was added to the cells. After
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effects (CPEs). The virus titer was calculated by the Reed–
Muench method [21].Effective stage analysis
To identify the step in the viral life cycle that is affected
by pimprinethine, WS-30581 A and WS-30581 B, vari-
ous concentrations of tested compounds were added to
cells according to the following three different treatment
procedures. (i) To analyze for a preventive effect (before
infection), the compounds were added to cells for 2 h at
37°C followed by washing with maintenance medium
(MM) before virus infection. (ii) To analyze for inhib-
ition of adsorption (during infection), the mixtures of
the compounds and virus were added to cells for 2 h at
37°C followed by washing with MM. (iii) To analyze for
a therapeutic effect (post infection), the cells were first
infected for 1 h at 37°C followed by washing with MM,
the compounds were added and incubated with the cells
for the duration of the experiment. For all treatments,
cell viability and progeny virus yields were measured
after 48 h of infection.Adsorption analysis
Cells were infected with EV71 (104 TCID50) containing
160 μM pimprinethine, 80 μM WS-30581 A or 80 μM
WS-30581B, after 2 h adsorption at 37°C, inoculum was
discarded, cells were washed three times with phosphate
buffered saline (PBS) and harvested following freeze-
thaw cycles, and subjected to virus titration. Cells in-
fected with EV71, but treated in the absence of tested
compounds, were used as a virus control.Release analysis
RD cells were treated with or without 80 μM pimpri-
nethine, 40 μM WS-30581 A or 40 μM WS-30581 B
after 100 TCID50 of EV71 infection; Supernatants and
cells were harvested together or separately for determin-
ation of progeny virus yields at 12 h p.i. by the method
of Reed and Muench [21].Time of (drug) addition experiment
RD cells were infected with 100 TCID50 of EV71 and
then 80 μM pimprinethine, 40 μM WS-30581 A and
WS-30581 B were added at different time phases (−1–
0 h, 0–10 h, 2–10 h, 4–10 h, 6–10 h, 8–10 h and −1–
10 h pi, where −1–0 h is the viral infection period and
0–10 h is the period for virus proliferation in the cells).
The cells and supernatants were harvested at 10 h post-
infection (pi) and subjected to three freeze-thaw cycles,
after which the viruses were titered by the Reed–Muench
method [21].RNA extraction and quantitative reverse transcription-PCR
The EV71 RNA was extracted from infected cells and cul-
ture supernatants with TRIzol (Invitrogen) and reverse-
transcribed using a PrimeScript RT reagent Kit (Takara)
according to the manufacturer’s instructions. The prod-
ucts of reverse transcription were quantified with the
SYBR Premix Ex Taq II(perfect real time)Kit (TaKaRa)
and detected with a Step One Plus sequence detection sys-
tem (Applied Biosystems). Expression of actin was used
as an internal standard. The special primer sequences
were: EV71-VP1-F: 5'-CACACAGGTGAGCAGTCATC
G-3', EV71-VP1-R: 5'-GTCTCAATCATGCTCTCGT CA
CT-3'; Actin-F: 5'-GGCGGGACCACCATGTACCCT-3',
Actin-R: 5'-AGGGGCCGGA CTCGT CATACT-3'.Immunofluorescence assay
The RD cells infected with EV71 in a 24-well plate were
fixed with 4% paraformaldehyde for 20 min and perme-
abilized with 0.5% Triton X-100 (in PBS) for 20 min, then
blocked with 1% bovine serum albumin for 30 min, and
subsequently incubated with the primary antibody (mouse
anti-enterovirus 71 monoclonal antibody) for 2 h, followed
by the appropriate Alexa-Fluor-488-labeled secondary
antibody (Alexa-Fluor- 488-conjugated AffiniPure goat
anti-mouse IgG (H + L)) for 60 min. Cell nuclei were
stained with 40, 6-diamidino-2-phenylindole (DAPI). After
each step, the slides were washed repeatedly with PBS
with Tween (PBST). Fluorescence was observed and re-
corded using a confocal laser- scanning microscope.Flow cytometry analysis
For the apoptosis assay, the RD cells in 6-well plates in-
fected with 100 TCID50 of EV71 were left untreated or
treated with 80 μM pimprinethine, 40 μM WS-30581 A
and WS-30581 B for 36–48 h, until the CPEs of virus con-
trol cells reached 70–80%. The cells were stained with
Annexin-V-fluorescein and propidium iodide, according
to the manufacturer’s instructions and subsequently sub-
jected to flow cytometry analysis.Statistical analysis
Experimental results are expressed as means of at least
three independent experiments. Values are expressed as
means ± standard deviations (SD). Comparisons between
experimental and control groups were performed using
the unpaired Student’s t-test. In all cases, p <0.05 was
considered significant.
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